Adma Biologics IncADMA
Price$10.03Intrinsic value$19.3092% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $512.3M+20.1% YoYTTM through 30 Jun 2026
Net Income $169M-14.5% YoYTTM through 30 Jun 2026
Free Cash Flow $116.5MTTM through 30 Jun 2026

Margins

Current
Gross Margin71.0%
EBITDA Margin45.3%
Operating Margin50.9%
Net Margin33.0%

Returns

11.6%ROE
24.7%ROA
36.0%ROIC

Balance Sheet Health

Debt / Equity0.50x
Current Ratio6.95x
Net Debt$58.7M
Cash & Equivalents$136M

Quality Metrics

Altman Z-Score7.24
Piotroski F-Score7 / 9
FCF Margin22.7%
Rule of 4027.2
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $510.2M
Diluted EPS$0.70TTM
'20'21'22'23'24'25
FY2025: $0.60

Dividend

No dividend

Capital Allocation

R&D Spend$11.5M
Capex Intensity4.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.